Marker Therapeutics, Inc. · NASDAQ:MRKR
Marker Therapeutics — Investor Presentation (August 2025)
28 slides from Marker Therapeutics's investor presentation, Aug 26, 2025
Slide 1: Marker Therapeutics Corporate Presentation
MARKER THERAPEUTICS CORPORATE PRESENTATION August 26, 2025 NASDAQ: MRKR
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements contained herein are forward - looking statements within the meaning of Section 21 E of the Securities Exchange Act of 1934 , as amended, and Section 27 A of the Securities Act of 1933 , as amended, that involve risks and uncertainties . All statements o
Slide 3: Marker Therapeutics – Value Proposition
3 MAR - T Cell Platform MAR - T (Multi - Antigen Recognizing T cell, formerly known as multiTAA) technology was developed at Baylor College of Medicine and, we believe, offers key therapeutic and manufacturing advantages over traditional T cell therapies Attractive Safety Profile MAR - T cells are n
Slide 4: MAR-T Technology
MAR - T Technology 4
Slide 5: Mechanism of Action of MAR-T Cells
5 • MAR - T cells target up to 6 antigens 1, 2 for a more potent, durable anti - tumor response. • MAR - T cells lack genetic modification; Natural T cells expanded ex vivo pose no mutagenesis risk. • MAR - Ts intend to address challenges faced by Bispecific Antibodies, CAR - T and TCR approaches. •
Slide 6: MAR-T Cells are Generated in a Simple Manufacturing Process
• No genetic engineering • Natural T cell expansion • Uninterrupted cell expansion • Reproducible process • Cost - effective process PBMC, peripheral blood mononuclear cells. 6 MAR - T Cells are Generated in a Simple Manufacturing Process
Slide 7: MAR-T Pipeline for Hematologic Malignancies and Solid Tumors
MAR - T Pipeline for Hematologic Malignancies and Solid Tumors 7 PHASE 2 PHASE 1 IND PRECLINICAL PROGRAM / INDICATION HEMATOLOGIC MALIGNANCIES MT - 601 1 (APOLLO) Lymphoma – Autologous MT - 401 - OTS 2 AML – Allogenic Off - the - Shelf (OTS) SOLID TUMORS MT - 601 1 Pancreatic Cancer – Autologous AML
Slide 8: MT-601 APOLLO Study
MT - 601 – APOLLO STUDY MAR - Ts targeting 6 tumor antigens for patients with lymphoma who relapsed after anti - CD 19 CAR - T cells or where CAR - T cell therapy is not an option 8
Slide 9: APOLLO Study Utilizes an Optimized MAR-T Cell Product
APOLLO Study Utilizes an Optimized MAR - T Cell Product 9 MARKER’S MT - 601 STUDY (APOLLO) BAYLOR STUDY (1) • MAR - T cell product targeted 5 tumor antigens • Demonstrated durable responses for up to 5 years without CRS or ICANS • Cell Dose: 10x10 6 – 40x10 6 • Manufacturing Process: • Average Poten
Slide 10: Marker APOLLO Clinical Trial Design
Marker MT - 601 APOLLO Clinical Trial Design Lymphoma Patient 10 MT - 601 Dose Escalation 100 - 400 x 10 6 cells N=24 STUDY DESIGN Enroll different histopathologies (e.g. DLBCL, FL, MZL, MCL, HL) Histopathology - specific (DLBCL – CAR - T and/or Bispecific relapse) DLBCL, Diffuse Large B Cell Lympho
Slide 11: Early Objective Responses in Participants with NHL
MT - 601 Shows Early Objective Responses in Participants with Non - Hodgkin Lymphoma (NHL) 20 0 Best Response 40 60 80 100 Percentage (%) Complete Response Partial Response Progressive Disease ORR=66% CRR=50% N = 12 Study participant diagnosed with LBCL had 10 prior treatment lines (incl . bispecifi
Slide 12: Patients Treated in Phase 1 APOLLO Trial – Non-Hodgkin Lymphoma
0 3 6 18 007 - 601 007 - 603 007 - 604 009 - 603 008 - 601 009 - 601 010 - 601 010 - 602 004 - 602 007 - 602 001 - 602 005 - 601 Patients Treated 12 Patients Treated in Phase 1 APOLLO Trial – Non - Hodgkin Lymphoma 9 12 15 Months Follow - Up MT - 601 infusion ǂ Complete Response Partial Response ǂ C
Slide 13: Study Participants with NHL show Early Objective Responses
13 Study Participants with NHL show Early Objective Responses Complete Response Partial Response CR, Complete Response; PR, Partial Response; PD, Progressive Disease; LD, Lymphodepletion; FL, Follicular Lymphoma; LBCL, Large B Cell Lymphoma; MZL , Marginal Zone Lymphoma; MCL, Mantle Cell Lymphoma. B
Slide 14: Study Participants with HL show Early Objective Responses
14 Study Participants with HL show Early Objective Responses HL, Hodgkin’s Lymphoma. (1) Patient scan provided by Dr. Haitham Abdelhakim (University of Kansas). 40 Percentage (%) 20 0 Best Response Progressive Disease Partial Response Complete Response Response Rates N = 9 100 80 60 ORR=78% CRR=11%
Slide 15: Appears Safe and Well Tolerated
MT - 601 Appears Safe and Well Tolerated No Dose Limiting Toxicities (DLTs) reported (doses tested ranged from 100x10 6 to 400x10 6 cells) 2 Grade 1 CRS events reported (fever; no treatment required) No ICANS reported Long term toxicities currently being assessed CRS, Cytokine Release Syndrome; ICAN
Slide 16: Insights from Geoffrey Shouse, D.O., Ph.D.
INSIGHTS FROM GEOFFREY SHOUSE, D.O., Ph.D. Assistant Professor, City of Hope, Duarte, CA
Slide 17: Complete Response in CAR-Relapsed DLBCL Patient
Complete Response in CAR - Relapsed DLBCL Patient Treated with MT - 601 17 Before MT - 601 treatment 8 weeks after MT - 601 treatment
Slide 18: Complete Response in Patient with FL Transformed to DLBCL
Complete Response in Patient with FL Transformed to DLBCL Treated with MT - 601 after CAR - T and Bispecific Relapse 18 Before MT - 601 treatment 8 weeks after MT - 601 treatment
Slide 19: Complete Response in DLBCL Patient After CAR-T and Bispecific Relapse
Complete Response in DLBCL Patient Treated with MT - 601 after CAR - T and Bispecific Antibody Relapse 19 Before MT - 601 treatment 4 weeks after MT - 601 treatment
Slide 20: Partial Response in Patient with FL Transformed to DLBCL
Partial Response in Patient with FL Transformed to DLBCL 20 Before MT - 601 treatment 8 weeks after MT - 601 treatment
Slide 21: Treatment Landscape in CAR-Relapsed DLBCL Patients
Treatment Landscape in CAR - Relapsed DLBCL Patients
Slide 22: Unmet Needs in DLBCL
Unmet Needs in DLBCL • The treatment landscape has seen dramatic changes and continues to undergo changes associated with incorporation of novel therapies . • Even with these changes, unmet needs persist including patients that relapse after available treatments including CAR - T, stem cell transpla
Slide 23: Current Treatment Landscape in CAR-Relapsed DLBCL
23 BsAbs ADCs Epcoritamab Loncastuxumab Glofitamab Polatuzumab APPROVED THERAPIES Monoclonal Antibodies Tafasitamab w/R) Others Selinexor BVR - R Current Treatment Landscape in CAR - Relapsed DLBCL BsAbs – Likely best available • Durability of response unclear Tafa/len – Limitations of efficacy and
Slide 24: Current Treatment Landscape: Therapies in Development
24 THERAPIES IN DEVELOPMENT alloCAR - Ts Dual/Tri - Specific CAR - Ts TCEs huCART19 - IL18 CAR - NKs in vivo CAR - Ts Small Molecules Current Treatment Landscape in Patients with CAR - Relapsed DLBCL • Most treatments under development use CD19/CD20 targets (used by prior LoT) minimizing utility of
Slide 25: Current Treatment Landscape in Patients with CAR-Relapsed DLBCL
25 THERAPIES IN DEVELOPMENT BsAbs ADCs Epcoritamab Loncastuxumab Glofitamab Polatuzumab APPROVED THERAPIES Monoclonal Antibodies Tafasitamab Others Selinexor BVR - R alloCAR - Ts TCEs Dual/Tri - Specific CAR - Ts huCART19 - IL18 CAR - NKs in vivo CAR - Ts Small Molecules Current Treatment Landscape
Slide 26: Poised to Fill Unmet Needs in DLBCL
MT - 601 Poised to Fill Unmet Needs in DLBCL • Despite the promise of novel therapies in DLBCL, unmet needs persist . • MT - 601 has demonstrated exceptional safety and preliminary efficacy and carries the potential to fill many of these unmet needs. 26
Slide 27: Marker APOLLO Clinical Trial Design
Marker MT - 601 APOLLO Clinical Trial Design Lymphoma Patient 27 MT - 601 Dose Escalation 100 - 400 x 10 6 cells N=24 STUDY DESIGN Enroll different histopathologies (e.g. DLBCL, FL, MZL, MCL, HL) Histopathology - specific (DLBCL – CAR - T and/or Bispecific relapse) DLBCL, Diffuse Large B Cell Lympho
Slide 28: Thank You
THANK YOU 28
Marker Therapeutics — Investor Presentation (August 2025) on 6ix